Total Payments
$572,532
2024 Payments
$10,705
Companies
62
Transactions
1,788
Medicare Patients
6,758
Medicare Billing
$2.3M
Payment Breakdown by Category
Consulting$231,079 (40.4%)
Other$216,240 (37.8%)
Travel$57,575 (10.1%)
Food & Beverage$34,956 (6.1%)
Research$26,905 (4.7%)
Education$5,778 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $231,079 | 141 | 40.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $216,240 | 125 | 37.8% |
| Travel and Lodging | $57,575 | 206 | 10.1% |
| Food and Beverage | $34,956 | 1,254 | 6.1% |
| Unspecified | $26,905 | 6 | 4.7% |
| Education | $5,778 | 56 | 1.0% |
Payments by Type
General
$545,627
1,782 transactions
Research
$26,905
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $226,649 | 489 | $0 (2024) |
| Radius Health, Inc. | $110,957 | 191 | $0 (2024) |
| Lilly USA, LLC | $101,931 | 233 | $0 (2024) |
| Eli Lilly and Company | $86,837 | 137 | $0 (2021) |
| PFIZER INC. | $12,255 | 122 | $0 (2024) |
| GlaxoSmithKline, LLC. | $9,760 | 66 | $0 (2024) |
| Sandoz Inc. | $7,700 | 1 | $0 (2024) |
| Celltrion, Inc. | $2,737 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $2,097 | 70 | $0 (2024) |
| ABBVIE INC. | $2,051 | 91 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,705 | 118 | Sandoz Inc. ($7,700) |
| 2023 | $29,556 | 160 | Radius Health, Inc. ($16,673) |
| 2022 | $5,242 | 161 | Radius Health, Inc. ($1,622) |
| 2021 | $65,844 | 181 | Eli Lilly and Company ($30,765) |
| 2020 | $84,935 | 158 | Eli Lilly and Company ($36,688) |
| 2019 | $111,930 | 256 | Amgen Inc. ($65,650) |
| 2018 | $94,239 | 290 | Lilly USA, LLC ($44,659) |
| 2017 | $170,081 | 464 | Amgen Inc. ($105,487) |
All Payment Transactions
1,788 individual payment records from CMS Open Payments — Page 1 of 72
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.81 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Sandoz Inc. | — | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $31.48 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $34.78 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/27/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Bone Health | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.21 | General |
| 11/12/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $34.70 | General |
| 11/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $30.88 | General |
| Category: Inflammation | ||||||
| 10/30/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: OSTEOPOROSIS | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Immunology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: Inflammation | ||||||
| 10/21/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Endocrinology | ||||||
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Bone Health | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.96 | General |
| 10/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.75 | General |
| Category: Dermatology | ||||||
| 10/09/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/08/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study Concepts on Patient Preference - to support the value story of ABL's MTS | Radius Health, Inc. | $17,090 | 2 |
| NA North America PROLIA Prospective Persistence Study | Amgen Inc. | $5,330 | 1 |
| TANEZUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Direct and Indirect Costs Associated with Osteoporotic Fracture | Amgen Inc. | $912.41 | 1 |
| A randomized study to evaluate the efficacy and safety of abaloparatide-sMTS for the treatment of postmenopausal women with osteoporosis | Radius Health, Inc. | $372.06 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,949 | 40,688 | $1.2M | $688,563 |
| 2022 | 14 | 1,795 | 43,716 | $1.2M | $698,488 |
| 2021 | 19 | 1,663 | 21,158 | $1.5M | $508,618 |
| 2020 | 10 | 1,351 | 18,414 | $811,905 | $407,645 |
Total Patients
6,758
Total Services
123,976
Medicare Billing
$2.3M
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 199 | 19,500 | $557,305 | $357,830 | 64.2% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 18 | 18,480 | $277,200 | $146,688 | 52.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 446 | 1,056 | $158,400 | $102,294 | 64.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 108 | 162 | $56,700 | $21,728 | 38.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $22,100 | $11,536 | 52.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 132 | $17,160 | $9,192 | 53.6% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 186 | 189 | $33,075 | $8,257 | 25.0% |
| 77089 | Calculation of trabecular bone score (tbs) using imaging data with interpretation and report on fracture risk | Office | 2023 | 225 | 228 | $22,800 | $7,788 | 34.2% |
| 77081 | Dxa bone density measurement of forearm, finger, hand, or foot | Office | 2023 | 196 | 196 | $14,700 | $7,022 | 47.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 237 | 470 | $21,150 | $5,376 | 25.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 35 | 43 | $10,750 | $3,476 | 32.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 35 | 52 | $8,002 | $3,083 | 38.5% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 28 | 47 | $4,700 | $1,725 | 36.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 35 | 38 | $2,470 | $1,715 | 69.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 12 | $1,500 | $639.39 | 42.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 19 | 19 | $1,520 | $210.56 | 13.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 204 | 21,366 | $534,150 | $363,677 | 68.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2022 | 19 | 19,741 | $296,115 | $149,082 | 50.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 512 | 1,188 | $178,200 | $116,328 | 65.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 94 | 94 | $34,400 | $16,279 | 47.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 75 | 101 | $35,350 | $14,761 | 41.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 136 | $16,150 | $9,085 | 56.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 170 | 172 | $30,075 | $7,420 | 24.7% |
| 77089 | Calculation of trabecular bone score (tbs) using imaging data with interpretation and report on fracture risk | Office | 2022 | 186 | 188 | $18,850 | $6,840 | 36.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 242 | 504 | $22,760 | $5,834 | 25.6% |
About Dr. Stuart Silverman, MD
Dr. Stuart Silverman, MD is a Specialist healthcare provider based in Beverly Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679670822.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Silverman, MD has received a total of $572,532 in payments from pharmaceutical and medical device companies, with $10,705 received in 2024. These payments were reported across 1,788 transactions from 62 companies. The most common payment nature is "Consulting Fee" ($231,079).
As a Medicare-enrolled provider, Silverman has provided services to 6,758 Medicare beneficiaries, totaling 123,976 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Beverly Hills, CA
- Active Since 09/20/2006
- Last Updated 12/15/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1679670822
Products in Payments
- Prolia (Biological) $124,041
- FORTEO (Drug) $101,412
- EVENITY (Biological) $71,069
- Tymlos (Biological) $54,378
- Tymlos (Drug) $16,242
- Enbrel (Biological) $2,220
- XELJANZ (Drug) $1,463
- COSENTYX (Biological) $1,206
- Strensiq (Drug) $1,083
- STELARA (Biological) $1,048
- RINVOQ (Biological) $979.72
- BENLYSTA (Biological) $915.61
- TALTZ (Drug) $822.41
- Humira (Biological) $603.31
- COSENTYX (Drug) $594.75
- SIMPONI ARIA (Biological) $592.92
- ACTHAR (Biological) $500.23
- SAPHNELO (Biological) $392.38
- LYRICA (Drug) $365.59
- Otezla (Drug) $336.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Beverly Hills
Dr. Norman Lepor, M.d, M.D
Specialist — Payments: $3.0M
Specialist $3.0M
Dr. Michael Bush, M.d, M.D
Specialist — Payments: $614,437
Specialist $614,437
Dr. Suzanne Gilberg-Lenz, M.d, M.D
Specialist — Payments: $319,119
Specialist $319,119
Dr. Todd Lanman, M.d., F.a.c.s, M.D., F.A.C.S
Specialist — Payments: $308,676
Specialist $308,676
Dr. Hooman Melamed, M.d, M.D
Specialist — Payments: $202,585
Specialist $202,585
Dr. David Stoll, M.d, M.D
Specialist — Payments: $178,145
Specialist $178,145